Phio Pharmaceuticals Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Phio Pharmaceuticals Corp. on March 30, 2026. The report discloses a material event under Item 8.01 (Other Events) regarding the company's clinical supply chain operations.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate event rather than financial performance data.
Material Changes
On March 30, 2026, the Company entered into a cGMP (current Good Manufacturing Practice) drug product manufacturing services agreement with a U.S. manufacturer. This agreement is intended to secure clinical supply for the Company's drug development programs.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or specific risk factors beyond the context of the manufacturing agreement. The full details of the event are contained in the press release attached as Exhibit 99.1.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific terms of the manufacturing agreement.
- Verify the identity and capacity of the U.S. manufacturer selected for clinical supply.
- Confirm the timeline for the initiation of clinical supply production.
- Check subsequent filings for any financial impact or cost implications of this agreement.